Research published in conjunction with the 2018 American Society of Clinical Oncology Annual Meeting presented new findings on the use granulocyte-colony stimulating factor agents in treating febrile neutropenia (FN) and in peripheral stem cell mobilization.
Research published in conjunction with the 2018 American Society of Clinical Oncology Annual Meeting presented new findings on the use granulocyte-colony stimulating factor (G-CSF) agents in treating febrile neutropenia (FN) and in peripheral stem cell mobilization.
Differences in AEs with G-CSFs may be due to differing baseline characteristics
G-CSF agents are widely used to treat and prevent chemotherapy-induced FN, and a study published in abstract examined characteristics of patients receiving reference filgrastim (Neupogen), the FDA-approved biosimilar filgrastim (Zarxio), and the FDA-approved follow-on filgrastim (tbo-filgrastim, which was approved prior to the establishment of a US biosimilar regulatory pathway) together with adverse events (AEs).1
In total, 5470 patients were included, with 4155 receiving reference filgrastim, 771 receiving tbo-filgrastim, and 544 receiving biosimilar filgrastim.
Patients who received the reference were more likely to be male (45%) than were patients who received the follow-on (40%) or the biosimilar (36%), and they were more likely to have a diagnosis of leukemia than other cancers.
Patients who received the follow-on were more likely to experience the following AEs than those who received the reference: cough (5.4%, 3.4%), dizziness (3.0%, 1.3%), dyspnea (9.5%, 7.2%), fatigue (10.2%, 7.1%), and thrombocytopenia (15.6%, 12.7%).
Patients receiving the biosimilar had lower rates of the following AEs than patients who received the reference: arthralgia (0.9%, 3.4%), anemia (18.6%, 24.8%), fatigue (4.2%, 7.1%), and thrombocytopenia (7.9%, 12.7%). However, those receiving the biosimilar had higher rates of dizziness than those receiving the reference (3.1%, 1.3%).
The researchers state that the differences in demographic and clinical characteristics of the patients who received each of the 3 products could be due to differences in cancer type and age, or factors such as provider preferences and reimbursement policies; as the safety profiles of the products are similar, the differences in rates of AEs may explained by differences in the baseline characteristics of the patients.
Using biosimilar filgrastim could lead to faster neutrophil and platelet engraftment
In addition to its use in preventing FN, biosimilar filgrastim, Zarxio, is also approved for peripheral stem cell mobilization.
A retrospective analysis compared the efficacy of the biosimilar with that of reference filgrastim for peripheral stem cell mobilization, and found no difference in the yield of CD34+ cells in patients who received the 2 treatments.2 However, using the biosimilar resulted in a significantly shorter time to neutrophil and platelet engraftment.
The study analyzed patients with multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma who were undergoing autologous hematopoietic stem cell transplantation at a single center from 2015 to 2017. All patients had peripheral blood stem cell mobilization with subcutaneous doses of 10 µg/kg per day of either the biosimilar or the reference filgrastim at on days 1 to 5 (with apheresis performed on day 5).
In total, 80 patients were included; 25 received the biosimilar and 55 received the reference filgrastim.
The median yield of CD34+ cells per kg for patients receiving the biosimilar versus the reference was similar at 5.19 (±3.02) and 4.58 (±2.43), respectively (P =.34). However, the median number of days to neutrophil engraftment was 10.8 (±1.78) for the biosimilar group and 12.0 (±2.83) for the reference group (P =.57), and the median number of days to platelet engraftment was 16.8 (±4.13) for the biosimilar group and 19.7 (±5.09) for the reference group (P =.02).
The researchers say that these finding should be confirmed by a large, randomized controlled trial, as engraftment is key in transplantation.
References
1. Irwin DE, Brady BL. Adverse events with G-CSF for neutropenia in cancer. J Clin Oncol. 2018;36 (suppl; abstr e18762).
2. Young D, Reddy PS, Mattar BI, et al. A retrospective analysis comparing efficacy of filgastrim-sndz versus filgastrim for autologous, peripheral stem cell mobilization in patients with multiple myeloma and lymphoma. J Clin Oncol. 2018;36 (suppl; abstr e19505).
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.